BACKGROUND: Dopamine (DA) system dysfunction is implicated in the pathophysiology of major depressive disorder (MDD). We sought to determine if cigarette smokers with a history of MDD and current mild depressive symptoms have abnormal smoking-induced DA release (measured indirectly as change in (11)C-raclopride binding potential [BP(ND)]). METHODS: Fifty-six cigarette smokers either with (n = 10) or without (n = 46) a history of MDD (MDD+ and MDD-, respectively) underwent bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography, during which they smoked a regular cigarette. Presmoking to postsmoking changes in (11)C-raclopride BP(ND) were compared between groups. Also, correlations were determined between change in BP(ND) and depression, anxiety, and withdrawal rating scale scores for the MDD+ group. RESULTS: The MDD+ group had a significantly greater reduction in (11)C-raclopride BP(ND) (-16.3%) than the MDD- group (-8.4%) (analysis of covariance [ANCOVA], p = .03). Significant negative correlations were found between depression/anxiety and change in (11)C-raclopride BP(ND) (r = -.77, p < .01 and r = -.74, p = .01, respectively). CONCLUSIONS: MDD+ smokers have greater smoking-induced DA release than MDD- smokers, and higher depression/anxiety levels are associated with greater smoking-induced DA release. These findings support the theory that MDD+ smokers have DA system dysfunction, including heightened smoking-induced DA release.
BACKGROUND:Dopamine (DA) system dysfunction is implicated in the pathophysiology of major depressive disorder (MDD). We sought to determine if cigarette smokers with a history of MDD and current mild depressive symptoms have abnormal smoking-induced DA release (measured indirectly as change in (11)C-raclopride binding potential [BP(ND)]). METHODS: Fifty-six cigarette smokers either with (n = 10) or without (n = 46) a history of MDD (MDD+ and MDD-, respectively) underwent bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography, during which they smoked a regular cigarette. Presmoking to postsmoking changes in (11)C-raclopride BP(ND) were compared between groups. Also, correlations were determined between change in BP(ND) and depression, anxiety, and withdrawal rating scale scores for the MDD+ group. RESULTS: The MDD+ group had a significantly greater reduction in (11)C-raclopride BP(ND) (-16.3%) than the MDD- group (-8.4%) (analysis of covariance [ANCOVA], p = .03). Significant negative correlations were found between depression/anxiety and change in (11)C-raclopride BP(ND) (r = -.77, p < .01 and r = -.74, p = .01, respectively). CONCLUSIONS:MDD+ smokers have greater smoking-induced DA release than MDD- smokers, and higher depression/anxiety levels are associated with greater smoking-induced DA release. These findings support the theory that MDD+ smokers have DAsystem dysfunction, including heightened smoking-induced DA release.
Authors: W C Drevets; J C Price; D J Kupfer; P E Kinahan; B Lopresti; D Holt; C Mathis Journal: Neuropsychopharmacology Date: 1999-12 Impact factor: 7.853
Authors: J H Meyer; S Krüger; A A Wilson; B K Christensen; V S Goulding; A Schaffer; C Minifie; S Houle; D Hussey; S H Kennedy Journal: Neuroreport Date: 2001-12-21 Impact factor: 1.837
Authors: R E Carson; A Breier; A de Bartolomeis; R C Saunders; T P Su; B Schmall; M G Der; D Pickar; W C Eckelman Journal: J Cereb Blood Flow Metab Date: 1997-04 Impact factor: 6.200
Authors: R V Parsey; M A Oquendo; Y Zea-Ponce; J Rodenhiser; L S Kegeles; M Pratap; T B Cooper; R Van Heertum; J J Mann; M Laruelle Journal: Biol Psychiatry Date: 2001-09-01 Impact factor: 13.382
Authors: N D Volkow; J S Fowler; S J Gatley; S L Dewey; G J Wang; J Logan; Y S Ding; D Franceschi; A Gifford; A Morgan; N Pappas; P King Journal: Synapse Date: 1999-01 Impact factor: 2.562
Authors: Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; Zoe Allen-Martinez; David Scheibal; Anna L Abrams; Matthew R Costello; Judah Farahi; Sanjaya Saxena; John Monterosso; Edythe D London Journal: Neuropsychopharmacology Date: 2008-06-18 Impact factor: 7.853
Authors: Janet Audrain-McGovern; Daniel Rodriguez; Adam M Leventhal; Jocelyn Cuevas; Kelli Rodgers; Joseph Sass Journal: Nicotine Tob Res Date: 2012-03-01 Impact factor: 4.244
Authors: David R Strong; Suzanne N Haber; Audrey R Tyrka; Jennifer A Bernier; Steven A Rassmussen; Benjamin D Greenberg Journal: J Addict Med Date: 2012-03 Impact factor: 3.702
Authors: James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister Journal: Psychopharmacology (Berl) Date: 2010-05-18 Impact factor: 4.530
Authors: Kenneth A Perkins; Joshua L Karelitz; Grace E Giedgowd; Cynthia A Conklin; Michael A Sayette Journal: Psychopharmacology (Berl) Date: 2010-03-10 Impact factor: 4.530
Authors: Frank C Bandiera; Amanda Kalaydjian Richardson; David J Lee; Jian-Ping He; Kathleen R Merikangas Journal: Arch Pediatr Adolesc Med Date: 2011-04